Objective: To assess the effect of phytoestrogens on bone turnover and growth in adolescent boys. Design: Randomized double-blind placebo-controlled trial. Setting: Single school in northwest Tasmania. Participants: Adolescent boys (treatment n ¼ 69, placebo n ¼ 59, mean age 16.8 y). Interventions: Six weeks of isoflavone supplementation (Novasoy, 50 mg daily of isoflavone equivalents). Bone turnover markers (bone specific alkaline phosphatase (BAP) and pyridinoline creatinine ratio (PYR)) were measured at baseline and follow-up. Results: Despite marked increases in urinary genistein and daidzein in the treatment arm (both P < 0.001), there were no significant differences in BAP, PYR or short-term height or weight change. This applied to both intention-to-treat and per protocol analysis. Neither was there a significant correlation between urinary genistein and daidzein levels and BAP or PYR. Conclusions: Phytoestrogen supplementation to the level of usual Japanese dietary intake has no measurable effect on bone turnover in adolescent boys. Longer-term studies of bone density may be desirable but it is unlikely that there will be a large effect in either girls or boys given the lower endogenous oestrogen levels in boys.
Introduction
Fractures due to osteoporosis are a significant public health problem. There are well-documented differences in fracture incidence between Asian and Caucasian populations. The reason for this is not fully understood but may involve hip axis length variations (Wang et al, 1997) or phytoestrogen or isoflavone intake. It is estimated that Japanese intake is around 40 -50 mg of isoflavone per day (Kimira et al, 1998; Somekawa et al, 2001) , while Western intake is minimal. Studies in rats have suggested that both isoflavones (Fanti et al, 1998; Ishida et al, 1998; Picherit et al, 2001 ) and coumestrol (Draper et al, 1997) can prevent bone loss in the ovariectomy model, most likely through prevention of bone resorption (Ishida et al, 1998; Tsutsumi, 1995) . Human studies have provided conflicting results on the effect of these agents both on hot flushes (Dalais et al, 1998; Upmalis et al, 2000) and a variable, and possibly dose-dependent, effect on prevention of bone loss (Alekel et al, 2000; Dalais et al, 1998; Potter et al, 1998) , but uncertain effects on bone turnover (Wangen et al, 2000) . Fracture risk in later life is also affected by peak bone mass. However, there have been no studies of the effect of phytoestrogens in children or adolescents. Furthermore, males have lower estrogen levels than females and, in adult males, estrogen levels appear to be a stronger determinant of bone density than androgens (Falahati-Nini et al, 2000) . The aim of this study was to assess the effect of 6 weeks of isoflavone supplementation on bone turnover markers in adolescent boys.
Methods
The study was conducted in Burnie, Tasmania (latitude 42 S) at a single school (Hellyer College) between 5 July and 27 August 1999. All male students aged 16 -18 y were eligible to participate and were invited to participate through an information sheet sent to the home address and distributed through the school's daily newsletter. Of the 297 boys eligible, 136 volunteered and provided informed consent. The study was granted ethical approval by the University of Tasmania Human Research Ethics Committee (Project no. H0003116).
Subjects were randomly assigned to receive Novasoy (Archer Daniels Midland, 50 mg in total isoflavones) or identical placebo taken as tablets (round, 11 mm diameter). The randomization was determined by the manufacturer using computer-generated random numbers and subjects were allocated in the order determined by the manufacturer at their baseline appointment. Both subjects and field assistants were blinded. Compliance was assessed by tablet counts and urinary assays of genistein and daidzein at baseline and 6 weeks using high performance liquid chromatography as previously described (Dalais et al, 1998) .
Weight was measured to the nearest 0.1 kg (with shoes, socks and bulky clothing removed) using a single pair of electronic scales (Seca Delta Model 707), which were calibrated using a known weight at the beginning of each clinic. Height was measured to the nearest 0.1 cm (with shoes and socks removed) using a Leicester Height Measure (Child Growth Foundation). One observer (KH) performed all physical measurements. Tanner pubertal stage was selfassessed by questionnaire by using drawings made from Tanner's photographs illustrating the five stages of pubertal development. This approach has good agreement with actual examination in males (ICC 0.63; Morris & Udry, 1980) . Bone turnover was assessed at baseline and 6 weeks by two assays on first void morning urine samples. Bone formation was assessed by the bone-specific alkaline phosphatase immunoassay (Alkphase B, Metra Biosystems). It is highly specific for bone with a long half-life and responds rapidly to antiresorptive therapy in adults (Ettinger et al, 1999; Schnitzer et al, 2000) . The coefficient of variation (CV) in this study was 5.6%. Bone resorption was assessed by urinary deoxypyridinoline creatinine ratio measured by competitive immunoassay on a 20 ml aliquot taken from the urine collection, protected from light by a black bag and stored at 720 C prior to analysis (Pyrilinks-D, Metra Biosystems). The CV in this study was 6%. Urinary creatinine excretion was also assessed on a first void morning urine sample. Aliquots from each sample were diluted with neutral pH buffer and analysed by the Ektachem method. The CV was 5.4%.
Statistics
Descriptive variables are listed as means or percentages. Unpaired t-tests or Mann -Whitney U-tests (where appropriate) were utilized to compare baseline variable and change in short-term growth, bone turnover markers and urinary phytoestrogen assays. For the main hypotheses, analysis utilized both an intention-to-treat approach and a per protocol approach. For the latter, compliance was defined as achieving an increase in urinary genistein of 100 ng=mmol Cr or urinary daidzein of 200 ng=mmol Cr over baseline. A P-value less than 0.05 (two-tailed) or a 95% confidence interval not including the null point were regarded as statistically significant. All statistical analyses were performed on SPSS version 9.0 for Windows (Cary, NC, USA).
Results
A total of 136 boys enrolled in the trial. Four were outside the age limits and deemed ineligible. During the course of the trial four more subjects withdraw. A total of 128 boys completed the trial period: 69 in the treatment group and 59 in the placebo group. In a test of subject knowledge of allocation at the end of the trial period, 11.6 and 10.2% of subjects in the treatment and placebo groups, respectively, correctly ascertained which group they were assigned to. The remainder indicated that they did not know which group Phytoestrogens and bone turnover in boys G Jones et al they were in (76.8 and 83.1%) or they guessed incorrectly (11.6 and 6.7%). There was no significant difference in the level of knowledge of the groups (w 2 ¼ 0.07, P ¼ 0.80). Demographic and study factors are presented in Table 1 . There were no significant differences in baseline factors between those assigned to isoflavone or placebo. Children were either Tanner stage 4 (n ¼ 61) or 5 (n ¼ 67) at baseline. Sixty percent of children increased their height (by any amount) during the study timeframe.
There were significant increases in both the pyridinoline creatinine ratio (PYR; difference 0.58, 95% CI 0.12 -1.05) and bone-specific alkaline phosphatase (BAP; difference 8.95 units, 95% CI 7.12 -10.78) during the study timeframe, possibly due to the effect of winter. Isoflavone supplementation increased both urinary daidzein and genistein levels compared to placebo (both P < 0.001), however, there were no significant differences between the two groups in PYR, BAP, height change or weight change (Table 2) .
Per protocol analysis also revealed no significant differences between the two groups in BAP (þ0.53 IU, 95% CI 73.32, þ4.37) or PYR (þ0.35 nmol=mmol creatinine, 95% CI 70.61, þ1.32). Lastly baseline genistein or daidzein levels in urine did not correlate with either BAP or PYR at baseline (maximum r 70.07, P ¼ 0.40) and follow-up levels did not correlate with follow up bone turnover markers (maximum r 70.11, P ¼ 0.25).
Discussion
In this randomized trial, supplementation with isoflavones to the level of usual Japanese intakes markedly increased urinary genistein and daidzein (indicating reasonable compliance), but had no discernible effect on bone formation, bone resorption or short-term growth in either intention to treat or per protocol analysis.
Assessment of bone health in children is more difficult due the combined effects of bone modelling and remodelling on bone turnover markers and size artefacts on bone density. Nevertheless, bone turnover markers do appear to have clinical utility in children (Szulc et al, 2000) . They predict longitudinal growth in infants up to 18 months of age (Lieuw-A-Fa et al, 1995) and children 4 -18 y (Rauch et al, 1994) as well as response to growth hormone supplementation in children (Marowska et al, 1996) , suggesting that they may be a valid short-term marker of bone changes. Furthermore, animal models have suggested that the mechanism by which isoflavones prevent bone loss is by suppression of bone turnover (Ishida et al, 1998; Tsutsumi, 1995) . They also predict the occurrence of fractures (van Daele et al, 1996) and longer-term changes in bone density but not accurately enough to be of use in an individual patient . While the correlation between bone turnover markers and development of bone mineralization in children is unknown, our results do not strongly support the need for further bone density studies. However, it remains possible that isoflavones have an effect on bone mineralization independent of bone turnover markers.
The phytoestrogen supplement we chose in this trial was clearly effective at increasing urinary excretion of genistein and daidzein. These agents are relatively weak binders to estrogen receptors (Kuiper et al, 1998) , but levels of exposure are also higher. It may be that a higher dose would have benefit as in the adult studies (Alekel et al, 2000) or different preparations such as coumestrols may have larger effects due to their stronger estrogen binding capacity (Kuiper et al, 1998) . Indeed, one study in rats showed a significant effect of coumestrol but not isoflavone supplementation on bone loss (Draper et al, 1997) .
While the use of a valid randomized design is a strength, this study has a number of potential limitations. Firstly, this study only included adolescent males due to their lower endogenous estrogen levels and the observation that low dose estradiol supplementation can accelerate ulnar growth in boys (Caruso-Nicoletti et al, 1985) . It is not possible to generalize to growing females; however, our results would suggest that supplementation may also be ineffective due their greater endogenous estrogen levels and hence greater competition for receptor binding. A time frame of 6 weeks may not be sufficient time to observe an effect on bone turnover; however, studies have shown a rapid response to both growth hormone (Lieuw-A-Fa et al, 1995) and estrogen (Kuiper et al, 1998) in children and markers of bone resorption change in line with daily salt intake ( Jones et al, 1997) , and within 1 month in adult studies of antiresorptives (Ettinger et al, 1999; Schnitzer et al, 2000) . Alternatively, it Phytoestrogens and bone turnover in boys G Jones et al may be that whole soy protein (containing isoflavones) may have biologically different actions to isolated isoflavones in a tablet formulation. Lastly, the sample size may have been insufficient. However, based on our data, we calculate that there was 80% power to detect a 16% difference in BAP and a 14% difference in PYR between groups. Smaller changes than this are unlikely to be of clinical significance as changes in the order of 30 -50% have been observed in clinical trials of both raloxifene and alendronate in women (Ettinger et al, 1999; Schnitzer et al, 2000) .
In conclusion, this short-term clinical trial of isoflavone supplementation demonstrates no significant effect on markers of bone resorption or short-term growth in adolescent boys.
